- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2011-05-04 11:26:17
- Reporting Period:
- Filing Date:
- Filing Date Changed:
- Accepted Time:
- 2011-05-04 12:26:17
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1080014||Theravance Inc||THRX||Pharmaceutical Preparations (2834)||943265960|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1131399||Plc Glaxosmithkline||980 Great West Road |
Brentford Middlesex X0 TW8 9GS
Reported Non-Derivative Transactions
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Common Stock||Acquisiton||2011-05-03||261,299||$25.60||6,163,577||No||4||P||Indirect||By Corporation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
- Common stock purchased pursuant to the right of GlaxoSmithKline LLC ("GSK LLC") under Section 2.1(d)(ii) of the Amended and Restated Governance Agreement by and among Theravance, Inc. (the "Issuer"), GSK LLC and GlaxoSmithKline plc dated as of June 4, 2004, as amended. Pursuant to Section 2.1(d)(ii), GSK LLC has the right to purchase from the Issuer, on a quarterly basis, sufficient shares of common stock to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity.
- The amount of Common Stock reported as beneficially owned by the Reporting Person following the reported transaction does not include the Reporting Person's previously disclosed beneficial ownership of 9,401,499 shares of Class A Common Stock of the Issuer (the "Class A Common Stock"), which are held of record by GSK LLC and Glaxo Group Limited ("GGL"), each of which is a wholly-owned subsidiary of the Reporting Person. Each share of Class A Common Stock may be converted into one share of Common Stock at any time.
- Shares of Common Stock are held of record by GGL.